Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has issued an update.
Cosmo Pharmaceuticals N.V. announced its participation in upcoming healthcare investor conferences in London and Windsor, where key executives will engage with investors through presentations and one-on-one meetings. These events are part of Cosmo’s strategy to strengthen investor relations and showcase its leadership in AI-driven healthcare and specialty pharmaceuticals.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). Founded in 1997 and headquartered in Dublin, Ireland, the company designs and manufactures advanced medical solutions trusted by global pharma and MedTech companies, aiming to empower patients and medical professionals through innovative technologies.
Average Trading Volume: 19,915
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
See more data about COPN stock on TipRanks’ Stock Analysis page.